10/524104

DT01 Rec'd PCT/PTC 1 0 FEB 2005

Docket No.: 3535-0138PUS1

(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:

Birkir SVEINSSON

Application No.: Not Yet Assigned

Confirmation No.: N/A

Filed: February 10, 2005

Art Unit: N/A

For:

USE OF CGRP ANTAGONIST

COMPOUNDS FOR TREATMENT OF

PSORIASIS

Examiner: Not Yet Assigned

INFORMATION DISCLOSURE STATEMENT (IDS)

MS PCT Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement accompanies the new patent application submitted herewith.

Copies of the references on the PTO/SB/08 are not provided.

Those documents which are marked with a double asterisk (**) next to the Cite No. in the attached form PTO/SB/08 (facsimile) are not supplied because they were previously cited by or submitted to the Office in a prior application number PCT/IS2003/000023, filed August 12, 2003.

10/524104

DT01 Rec'd PCT/PTC 1 0 FEB 2005

Application No.: Not Yet Assigned

Docket No.: 3535-0138PUS1

A concise explanation of relevance of the items listed on form PTO/SB/08 is in the form of an English language copy of a Search Report from a foreign patent office, issued in a counterpart application, which refers to the relevant portions of the references.

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this Information Disclosure statement shall not be construed to be an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

If necessary, the Commissioner is hereby authorized in this, concurrent, and future replies, to charge payment or credit any overpayment to our Deposit Account No. 02-2448 for any additional fees required under 37 C.F.R. § 1.16 or under § 1.17; particularly, extension of time fees.

Dated: February 10, 2005

KM/clb

Respectfully submitted,

Joe McKinney Muncy Registration No.: 32\334

BIRCH, STEWART, KOLÁSCH & BIRCH, LLP

8110 Gatehouse Rd

Suite 100 East

P.O. Box 747

Falls Church, Virginia 22040-0747

(703) 205-8000

Attorney for Applicant

DT01 Rec'd PCT/PTC 1 0 FEB 2005

PTO/SB/08a/b (08-03)

Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/B/PTO				Complete if Known		
				Application Number	Not Yet Assigned 24 1	
11	NFORMATION	I DI	SCLOSURE	Filing Date	February 10, 2005	
STATEMENT BY APPLICANT				First Named Inventor	Birkir SVEINSSON	
				Art Unit	N/A	
(Use as many sheets as necessary)				Examiner Name	Not Yet Assigned	
Sheet	1	of	1	Attorney Docket Number	3535-0138PUS1	

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No.1	Document Number	Publication Date	Name of Patentee or	Pages, Columns, Lines, Where	
		Number-Kind Code ² (if known)	MAN DD MOON	Applicant of Cited Document	Relevant Passages or Relevant Figures Appear	
	AA	US-6,214,816-B1	04-10-2001	Polivka Zden Eacute, K. et al.		

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No.1	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS					
		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²		
	CA**	NOVOTNY, Frantisek, "PSORIASIS TREATMENT BY HEPARIN", ACTA Universitatis Carolinae Medica, vol. 31, no. 3/4, 1985, pages 243-245.			
	CB**	YANLING, HE et al., "CALCITONIN GENE-RELATED PEPTIDE IN LANGERHANS CELLS IN PSORIATIC PLAQUE LESIONS", Chin Med. J., vol. 113, no. 8, 2000, pages 747-751.			
	CC**	CLAUDY, A, "LES NEUROMEDIATEURS EN DERMATOLOGIE. PERSPECTIVES THERAPEUTIQUES", Path Biol, vol. 44, no. 10, 1996, pages 888-894.			

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ** CITE NO.: Those document(s) which are marked with an double asterisk (**) next to the Cite No. are not supplied because they were previously cited by or submitted to the Office in a prior application relied upon in this application for an earlier filing date under 35 U.S.C. 120.

Examiner	Date	
Signature	Considered	

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.